Vaccine maker Adimmune Corp (國光生技) yesterday said it plans to start in August phase I clinical trials of its COVID-19 vaccine candidate, which effectively inhibited the growth of the novel coronavirus in preliminary animal tests last month.
Adimmune told a news conference in Taipei that it had designed and produced four prototypes of antigens to fight the virus based on its recombinant protein technology, and last month tested one prototype in a biosafety level 3 (BSL-3) lab at National Taiwan University (NTU).
After injecting the antigen into a few mice and seeing them generate antibodies, Adimmune extracted their plasma and placed it in another cell as well as the novel coronavirus to test the outcome, the company said.
Photo: Chien Hui-ju, Taipei Times
“The tests showed that the antibodies could inhibit the growth of the novel coronavirus and remained fully capable with a dilution of 1:640,” NTU Department of Clinical Laboratory Sciences and Medical Biotechnology professor Chang Sui-yuan (張淑媛) said.
The inhibition rate remained above 80 percent with a dilution of 1:1280, attesting to the strong effect of the vaccine candidate, Adimmune chairman Steve Chan (詹啟賢) said, adding that a flu vaccine is regarded as effective if its inhibition rate is higher than 80 percent with a dilution of 1:320.
The virus tested was from an isolated strain with the highest toxicity among NTU’s more than 20 isolated virus strains, Chang said.
“The tests gave us encouraging results and we feel confident. However, given that the novel coronavirus mutates, we need to run tests on more virus strains to see if the candidate will work against most of them,” she said.
The lab spent about one month setting up protocols and conducting tests, she added.
Adimmune does not know how long the vaccine candidate can protect humans from the virus, but would find out the answers in the clinical trials, Chan said.
The firm on Tuesday began the second stage of animal tests to see if the vaccine candidate would endanger mice and plans to complete the tests in October, he said.
While most vaccine developers have to wait for animal tests to be completed and for the results to be confirmed before moving on to human tests, Adimmune plans to expedite the process by applying to conduct human trials in August, Chan said.
Like other foreign regulators worldwide, Taiwan’s Food and Drug Administration has launched emergency use authorizations programs to speed up the development of a treatment for COVID-19, he said.
Adimmune has been included in the agency’s program and would be granted priority when applying for reviews or clinical trials, the company said.
After completing the animal tests’ interim analysis to make sure its candidate is safe, Adimmune would apply to conduct phase I clinical trials in August, and commence phase II and phase III trials in the first quarter next year, Chan said.
“We have to take some risks here for if the animal tests turn up negative, the phase I trial will have to stop,” he said.
The company’s goal is to start mass production of the vaccines in December if it gains approval of an emergency use authorization by the Taiwanese regulators, before gaining marketing approval next year, he said.
ADDITIONAL MEASURES: Washington is raising its restrictions on chipmakers in China to 14 nanometers, sources said, which might also affect TSMC plants The US is tightening restrictions on China’s access to chipmaking gear, two major equipment suppliers have said, underscoring Washington’s accelerating efforts to curb Beijing’s economic ambitions. Washington had banned the sale of most gear that can fabricate chips of 10 nanometers or better to Chinese firm Semiconductor Manufacturing International Corp (SMIC, 中芯國際) without a license. Now it has expanded that barrier to equipment that can make anything more advanced than 14 nanometers, Lam Research Corp chief executive officer Tim Archer told analysts. The moratorium likely extends beyond SMIC and includes other fabrication plants run by contract chipmakers operating in China, including
POKEMON-THEMED JET: An Airbus A321 would be painted with characters of the Japanese firm, which for the first time teams up with a foreign airline China Airlines Ltd (CAL, 華航) is planning to offer 40 percent more passenger flights this quarter than last quarter, as air travel demand is rising, the company said yesterday as it announced the launch of a Pokemon-themed jet. The airline is planning to paint one of its Airbus A321neo planes with a livery representing the Japanese animation, video game and mobile game franchise, China Airlines told a news conference in Taipei. Eleven Pokemon characters would be depicted on the fuselage, including Pikachu, Jigglypuff and Snorlax, while the Poke Ball, which players use to capture the characters in the games, would be depicted
China has begun a series of investigations into key figures responsible for shaping chip policy and investment, raising questions about the impact on Beijing’s blueprint for challenging US dominance of a US$550 billion industry. The top anti-graft agency this week launched an investigation into the minister who spearheads the country’s plan to build a world-class chip industry and wean itself off US silicon. Chinese Minister of Industry and Information Technology Xiao Yaqing (肖亞慶), whose agency oversees giants from Huawei Technologies Co (華為) to Xiaomi Corp (小米), became the most senior sitting cabinet member to face a disciplinary probe in almost four
One prototype air taxi suffered a software glitch, lost control and nosed into a field. Another’s computer erroneously thought it was on the ground, shutting off power in flight and plunging it into the pavement. Batteries on two more burst into flames. The race to develop a new family of flying machines to whisk people and cargo across traffic-choked cities has drawn billions of US dollars of investment and vast promise, but some of the biggest names in aviation have had accidents during testing,a Bloomberg review of reports dating back to 2018 showed. They include Boeing Co and its subsidiary, Aurora
RSS